NEXI

NexImmune (NEXI)

NexImmune Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:NEXI

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/14	08:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NEXI	NexImmune Inc
2024/06/12	06:17	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:NEXI	NexImmune Inc
2024/06/12	05:28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2024/05/21	06:10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NEXI	NexImmune Inc
2024/05/16	05:01	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:NEXI	NexImmune Inc
2024/05/10	01:39	Business Wire	Konzernabschluss zum 31. März 2024 verabschiedet, kontinuierliches Wachstum und Ausweitung der EBITDA-Marge, Aktienrückkaufprogramm in Höhe von 500 Millionen Euro gestartet	NASDAQ:NEXI	NexImmune Inc
2024/05/10	01:39	Business Wire	Approbation des résultats financiers du groupe au 31 mars 2024, poursuite de la croissance et de l’augmentation de la marge de BAIIA, lancement d’un programme de rachat d’actions de 500 millions €	NASDAQ:NEXI	NexImmune Inc
2024/05/09	15:00	Business Wire	Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, € 500 Million Share Buy-Back Program Launched	NASDAQ:NEXI	NexImmune Inc
2024/03/08	03:20	Business Wire	Konzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen Euro	NASDAQ:NEXI	NexImmune Inc
2024/03/08	02:33	Business Wire	Approbation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’euros	NASDAQ:NEXI	NexImmune Inc
2024/03/07	15:31	Business Wire	Approvati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprie	NASDAQ:NEXI	NexImmune Inc
2024/03/07	15:30	Business Wire	Group Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back Program	NASDAQ:NEXI	NexImmune Inc
2024/02/07	06:42	GlobeNewswire Inc.	NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:NEXI	NexImmune Inc
2024/02/07	06:30	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:NEXI	NexImmune Inc
2024/02/06	07:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2024/02/06	06:34	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:NEXI	NexImmune Inc
2024/02/03	04:00	GlobeNewswire Inc.	NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:NEXI	NexImmune Inc
2024/02/03	03:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2024/02/01	23:17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2024/01/20	06:43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2024/01/19	06:43	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:NEXI	NexImmune Inc
2023/12/23	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2023/12/02	03:39	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NEXI	NexImmune Inc
2023/11/23	07:40	Edgar (US Regulatory)	Form 144/A - Report of proposed sale of securities: [Amend]	NASDAQ:NEXI	NexImmune Inc
2023/11/23	07:34	Edgar (US Regulatory)	Form 144/A - Report of proposed sale of securities: [Amend]	NASDAQ:NEXI	NexImmune Inc
2023/11/23	07:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NEXI	NexImmune Inc
2023/11/22	06:39	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NEXI	NexImmune Inc
2023/11/21	07:19	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:NEXI	NexImmune Inc
2023/11/21	07:01	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:NEXI	NexImmune Inc
2023/11/18	06:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NEXI	NexImmune Inc